Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2019

View Archived Issues

Re-turning turncoat macrophages

Drug takes aim at TB enzyme and its backup

Prenatal treatment improves cystic fibrosis

Patient enrollment underway in phase I study of AGEN-1181

FDA approves IND application for Incysus' gamma-delta T-cell therapy

Sangamo and Pfizer announce phase I/II interim data for SB-525 gene therapy

Tesamorelin leads to significant reductions in liver fat in HIV patients with NAFLD

New Alzheimer's disease model differentiates the role of C99 from beta-amyloid

Fish slime helps turn the tide against antibiotic resistance

Novel series of reversible USP7 inhibitors as oncolytic drugs presented

Decreased intraocular inflammation observed in MAPLE wet AMD study of abicipar

Monoclonal antibody against CLDN18.2 shows development potential for gastric cancer

Bispecific molecule PRS-342 shows robust in vitro and in vivo antitumoral effects

eFFECTOR Therapeutics candidate targets RNA helicase eIF4A for cancer

Dragonfly Therapeutics patents NKG2D-binding proteins for cancer

Stoke Therapeutics divulges new antisense oligomers

Alector initiates first-in-human study of AL-003 for Alzheimer's disease

Altor BioScience identifies new fusion proteins for treatment of cancer

FDA clears Cellectis to begin phase I trial of UCARTCS1 in multiple myeloma

Aldeyra initiates phase III trial of reproxalap in dry eye disease

Mologen synthesizes new TLR9 agonists

Phase I data reported for shERPA agent TTC-352

ProQR Therapeutics discloses new HTT-targeting antisense oligonucleotides

New phase Ib/IIa trial studies RTB-101 for Parkinson's disease

Dermelix partners with EspeRare on DMX-101 for X-linked hypohidrotic ectodermal dysplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...